• Exo1 and the Translational Logic of Exocytic Control

  2026-08-18

  Exo1 offers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership perspective explains how translational researchers can use Exo1 as a causal perturbation tool when evaluating tumor extracellular vesicle biology, while maintaining a clear boundary between preclinical assay evidence and therapeutic claims.

• Bifendate (DDB) Workflows for Liver Research

  2026-08-18

  Build reproducible liver-cell, lipid-accumulation, autophagy, and drug-interaction assays with Bifendate (DDB). This practical guide connects formulation control and pathway-resolved readouts with CYP3A4 and P-glycoprotein safety workflows.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-08-17

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular signal that promotes M2 macrophage polarization through JAK2/STAT6 pathway engagement. Its findings connect a noncoding RNA cargo with an immunosuppressive tumor-microenvironment phenotype and provide a framework for testing pathway dependence in hepatocellular carcinoma models.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-17

  A 2025 study found that naturally occurring angiotensin peptide fragments can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, or NRP1 in receptor-specific patterns. The work identifies peptide length and tyrosine modification as important variables, while also showing why these findings require validation beyond antibody-based binding assays.

• PD 173074: Structure and Angiogenesis Inhibition

  2026-08-16

  The reference study established a structural explanation for how PD 173074 inhibits FGFR1 and suppresses FGF- and VEGF-driven angiogenesis. By combining kinase assays, mouse experiments, and 2.5 Å X-ray crystallography, it connected ATP-pocket binding with inhibitor selectivity and provided a framework for interpreting FGFR-directed antiangiogenic research.

• Bifendate (DDB): Dose, Lipids, and Assay Design

  2026-08-15

  Bifendate (DDB) is a hepatoprotection agent whose effects depend strongly on dose, timing, tissue, and assay context. This evidence-led guide reconciles its hepatoprotective applications with high-dose triglyceride elevations and translates those findings into better experimental design.

• Biotin Azide as a Molecular Audit Trail for Fzd5

  2026-08-14

  Biotin Azide enables selective click labeling of alkynylated biomolecules, creating a practical molecular audit trail for studying Fzd5–cholesterol–Wnt signaling. This guide connects reagent chemistry with assay design, controls, enrichment, and interpretation without overstating what the chemistry can prove.

• Protease Inhibitor Cocktail for TP53 Assays

  2026-08-14

  Learn how a Protease Inhibitor Cocktail protects TP53-centered protein assays in DHODH inhibitor studies. This guide connects cancer-metabolism findings with practical choices for Western blotting, co-immunoprecipitation, and EDTA-sensitive workflows.

• Cy3 NHS ester (non-sulfonated): Protocol Guide

  2026-08-13

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for amino groups on proteins, peptides, and nucleic acids when the workflow can tolerate an organic co-solvent. It is not appropriate for aqueous-only labeling or biomolecules that are sensitive to DMSO or DMF; a water-soluble sulfo-Cy3 NHS ester is a better choice in those cases.

• Açaí Extracts: Hepatocyte Cytotoxicity and Induction

  2026-08-13

  Raichura and colleagues evaluated consumer-relevant açaí extracts in sandwich-cultured human hepatocytes and complementary transporter assays. The study found extract-specific, time- and dose-dependent cytotoxicity, but little evidence of induction of major CYP enzymes or drug transporters, refining how botanical–drug interaction risks should be interpreted.

• ARCA Capped mRNA Synthesis with HyperScribe

  2026-08-12

  Discover how the HyperScribe All in One mRNA Synthesis Kit Plus 1 integrates ARCA capping, modified nucleotides, DNase treatment, and poly(A) tailing. This article connects molecular design choices to assay controls and emerging RNA vaccine development evidence.

• CCR7/DUSP1–iCAF Axis in HNSCC Growth

  2026-08-12

  The reference study connects CCR7 signaling in inflammatory cancer-associated fibroblasts with DUSP1 expression, TGF-β1 secretion, and head and neck squamous cell carcinoma behavior. Its integrated single-cell, cell-sorting, genetic perturbation, co-culture, and functional-assay design provides a mechanistic framework for studying how stromal cell states regulate tumor growth.

• SERCA2–CaN/FoxO1/FABP4 Axis in Atherosclerosis

  2026-08-11

  This 2025 study identifies the calcineurin/FoxO1/FABP4 pathway as a mechanistic link between SERCA2 dysfunction, abnormal macrophage lipid handling, foam cell formation, and atherosclerosis. Its combination of a SERCA2 C674S knock-in model, macrophage assays, metabolomics, and pharmacological intervention supports FABP4 inhibition as a strategy for testing how lipid metabolism contributes to vascular inflammation.

• FNPs for Stable Lung-Specific mRNA Delivery

  2026-08-11

  The reference study introduces five-element nanoparticles (FNPs) that combine poly(β-amino ester) helper polymers with DOTAP to improve both lung-directed mRNA delivery and formulation stability. Its structure–activity analysis and lyophilization results indicate a practical route toward mRNA formulations that retain activity during refrigerated storage.

• Netarsudil (AR-13324) for Reliable Cell Assays

  2026-08-10

  A scenario-based guide to using Netarsudil (AR-13324), SKU B7807, in cell viability, proliferation, cytotoxicity, and cytoskeletal workflows. It explains how ROCK biology, formulation properties, controls, and data interpretation affect reproducibility, while connecting the compound to emerging siRNA codelivery research.

16393 records 1/1093 page Next 12345 下5页 Last page